These inducement grants were approved by Compass Therapeutics Compensation Committee of the Board of Directors as a material inducement to employment. They were granted outside of the Company’s 2020 ...
Shares of Compass Pathways (NASDAQ:CMPS) lost ~35% in the premarket on Thursday after the psychedelic drug developer, with its Q3 2024 financials, announced plans to lay off staff amid a delay in its ...
We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience,” said Thomas Schuetz, MD, PhD, CEO ...
Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ depression, but investors appear unimpressed. The study ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported ...
COMPASS Pathways focuses on developing COMP360 psilocybin for treatment-resistant depression, facing significant challenges due to its Schedule I status. Key risks include market acceptance, ...
COMPASS Pathways PLC Sponsored ADR (CMPS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
Stocktwits on MSN
Psychedelics break out of the fringe under RFK Jr’s 2025 reset — but did MNMD or CMPS own the year?
With an estimated 51.5 million U.S. adults suffering from mental illness and the psychedelic drug market projected to grow at ...
Screening closed for all sites and final participants being scheduled for dosing On track for top-line 6-week primary endpoint results in late Q2 LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways ...
Per the consensus of Wall Street analysts, Compass Pathways (NASDAQ: CMPS) stock is on track for an absolutely stellar 12 months. They see its shares rising by 307% compared to where it is today. For ...
Detailed price information for Compass Therapeutics Inc (CMPX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback